MA47768A - Dosage et régime thérapeutiques pour la mélatonine - Google Patents

Dosage et régime thérapeutiques pour la mélatonine

Info

Publication number
MA47768A
MA47768A MA047768A MA47768A MA47768A MA 47768 A MA47768 A MA 47768A MA 047768 A MA047768 A MA 047768A MA 47768 A MA47768 A MA 47768A MA 47768 A MA47768 A MA 47768A
Authority
MA
Morocco
Prior art keywords
melatonin
regime
dosage
Prior art date
Application number
MA047768A
Other languages
English (en)
Inventor
Giancarlo Aquino
Fabrizio Facchinetti
Nicola Jayne Robertson
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA47768A publication Critical patent/MA47768A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047768A 2017-03-17 2018-03-14 Dosage et régime thérapeutiques pour la mélatonine MA47768A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17161472 2017-03-17

Publications (1)

Publication Number Publication Date
MA47768A true MA47768A (fr) 2021-06-02

Family

ID=58358443

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047768A MA47768A (fr) 2017-03-17 2018-03-14 Dosage et régime thérapeutiques pour la mélatonine

Country Status (4)

Country Link
EP (1) EP3595655B1 (fr)
ES (1) ES2972199T3 (fr)
MA (1) MA47768A (fr)
WO (1) WO2018167162A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021038601A1 (fr) 2019-08-30 2021-03-04 Vijayendrakumar Virendrakumarji Redasani Compositions pharmaceutiques liquides de mélatonine pour administration orale et parentérale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392903B1 (es) 2011-05-17 2014-01-17 Servicio Andaluz De Salud Preparación inyectable de melatonina
ITMI20112042A1 (it) 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
US9468626B2 (en) 2014-03-13 2016-10-18 Chiesi Farmaceutici S.P.A. Melatonin-based formulations for parenteral administration
EP3265058A1 (fr) 2015-03-04 2018-01-10 Industria Farmaceutica Galenica Senese S.r.l. Composition pharmaceutique pour l"administration parentérale de mélatonine, et son procédé de préparation

Also Published As

Publication number Publication date
EP3595655C0 (fr) 2024-02-07
WO2018167162A1 (fr) 2018-09-20
EP3595655A1 (fr) 2020-01-22
EP3595655B1 (fr) 2024-02-07
ES2972199T3 (es) 2024-06-11

Similar Documents

Publication Publication Date Title
EP3742944C0 (fr) Dosette et procédé de distribution
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
IL258931A (en) Therapeutic compounds and methods
IL259530A (en) Shape changing drug delivery devices and methods
EP3302442C0 (fr) Formes galéniques et leur utilisation
KR20180084759A (ko) 니들링 장치 및 약물 도포기
DK3703785T3 (da) Lægemiddelindgivelsesanordning
DK3280392T3 (da) Dosage regimens of amisulpride for treating nausea and vomiting
DK3468642T3 (da) Doseringsapparat og injektionsanordning
DK3380139T3 (da) Medikamentadministrationsanordning
EP3573614C0 (fr) Compositions pharmaceutiques pour thérapie combinée
EP3542773A4 (fr) Dispositif d'emballage de médicament
EP3463345A4 (fr) Combinaisons pharmaceutiques
EP3244868C0 (fr) Dispositifs d'administration de médicaments
EP3437644A4 (fr) Médicament
IL256451B (en) Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
DK3302478T3 (da) Pac-1 kombinations behandling
LT3383385T (lt) Melflufeno dozavimo režimas vėžio atveju
DK3558427T3 (da) Lægemiddelfremføringsanordning
EP3527216A4 (fr) Médicament
DK3349825T3 (da) Lægemiddeladministrationsanordning
IL269305A (en) Cannabinoid formulations and dosage
DK3449892T3 (da) Lægemiddeludleveringsapparat
DK3349827T3 (da) Lægemiddeladministrationsanordning
DK3694585T3 (da) Lægemiddelindgivelsesanordning